Morphologic and metabolic abnormalities in vertically HIV-infected children and youth

AIDS

Volumn 23, Issue 6, 2009, Pages 661-672

  Aldrovandi, Grace M ^a   Lindsey, Jane C ^b   Jacobson, Denise L ^d   Zadzilka, Amanda ^c   Sheeran, Elizabeth ^c   Moye, Jack ^d   Borum, Peggy ^e   Meyer III, William A ^f   Hardin, Dana S ^g   Mulligan, Kathleen ^h  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral therapy; Children and youth; Metabolic abnormalities; Morphological abnormalities; Protease inhibitors

Indexed keywords

AMPRENAVIR; DIDANOSINE; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LAMIVUDINE; LIPID; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ADULT; ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN BLOOD LEVEL; JUVENILE; LIPID ANALYSIS; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORPHOLOGY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SCHOOL CHILD; SERODIAGNOSIS; SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ADOLESCENT; ANTHROPOMETRY; ANTI-HIV AGENTS; BLOOD GLUCOSE; BODY COMPOSITION; CD4 LYMPHOCYTE COUNT; CHILD; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOSE TOLERANCE TEST; GROWTH; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INSULIN RESISTANCE; LIPIDS; MALE; PROGNOSIS; VIRAL LOAD; YOUNG ADULT;

EID: 64549140153     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283269dfb     Document Type: Article

References (70)

1. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR 3rd, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345:1522- 1528.
2. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
3. Resino S, Bellon JM, Resino R, Navarro ML, Tomas Ramos J, de Jose Ml, et al. Extensive implementation of highly active antiretroviral therapy shows great effect on survival and surrogate markers in vertically HIV-infected children. Clin Infect Dis 2004; 38:1605-1612.
4. Gibb DM, Duong T, Tookey PA, Sharland M, Tudor-WilliamsG, Novelli V, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003; 327:1019.
5. de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, Pezzotti P. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. J AM A 2000; 284:190-197.
6. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62.
7. Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds D, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006; 43:645-653.
8. Kaufman FR. Type 2 diabetes in children and youth. Endocrinol Metab Clin North Am 2005; 34:659-676; ix-x.
9. Shaw J. Epidemiology of childhood type 2 diabetes and obesity. Pediatr Diabetes 2007; 8 (Suppl 9): 7-15.
10. Cara JF, Chaiken RL. Type 2 diabetes and the metabolic syndrome in children and adolescents. Curr Diab Rep 2006; 6:241 - 250.
11. Ebbeling CB, Pawlak DB, Ludwig DS. Childhood obesity: public- health crisis, common sense cure. Lancet 2002; 360:473-482.
12. McComsey GA, O'Riordan M, Hazen SL, El-Bejjani D, Bhatt S, Brennan ML, et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS 2007; 21:921-927.
13. Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, Levy J. Prevalence of lipodystrophy in HIV-infected children: a cross- sectional study. Eur J Pediatr 2007; 166:13-21.
14. Ergun-Longmire B, Lin-Su K, Dunn AM, Chan L, Ham K, Sison C, et al. Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus. Endocr Pract 2006; 12:514-521.
15. Sanchez Torres AM, Munoz Muniz R, Madero R, Borque C, Garcia-Miguel MJ, De Jose Gomez Ml. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr 2005; 164:271-276.
16. Farley J, Gona P, Crain M, Cervia J, Oleske J, Seage G, Lindsey J. Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C. J Acquir Immune Defic Syndr 2005; 38:480-487.
17. Bitnun A, Sochett E, Dick PT, To T, Jefferies C, Babyn P, et al. Insulin sensitivity and beta-cell function in protease inhibitor- treated and -naive human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2005; 90:168-174.
18. Beregszaszi M, Dollfus C, Levine M, Faye A, Deghmoun S, Belial N, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV- infected children. J Acquir Immune Defic Syndr 2005; 40: 161-168.
19. Aldamiz-Echevarria L, Pocheville I, Sanjurjo P, Elorz J, Prieto JA, Rodriguez-Soriano J. Abnormalities in plasma fatty acid composition in human immunodeficiency virus-infected children treated with protease inhibitors. Acta Paediatr 2005; 94:672- 677.
20. Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV, et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics 2004; 114:e235-e242.
21. Rondanelli M, Caselli D, Trotti R, Solerte SB, Maghnie M, Maccabruni A, et al. Endocrine pancreatic dysfunction in HIV-infected children: association with growtn alterations. J Infect Dis 2004; 190:908-912.
22. MoraS, Zamproni I, BeccioS, Bianchi R, CiacometV, Vigano A. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus- infected children. J Clin Endocrinol Metab 2004; 89:24-28.
23. European Paediatric Lipodystrophy Croup. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004; 18:1443-1451.
24. Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003; 22:77- 84.
25. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21:405-410.
26. Wedekind CA, Pugatch D. Lipodystrophy syndrome in children infected with human immunodeficiency virus. Pharmacotherapy 2001; 21:861-866.
27. Melvin AJ, Lennon S, Mohan KM, Purnell JQ. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. AIDS Res Hum Retroviruses 2001; 17:1117-1123.
28. Babl FE, Regan AM, Pelton SI. Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals. Lancet 1999; 353:1243-1244.
29. Goran Ml, Gower BA. Longitudinal study on pubertal insulin resistance. Diabetes 2001; 50:2444-2450.
30. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tambor- lane WV. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 1986; 315:215-219.
31. Hirschfeld S. Dysregulation of growth and development in HIV-infected children. J Nutr 1996; 126:2641 S-2650S.
32. Gibson R. Principles of nutritional assessment. New York: Oxford University Press; 2005.
33. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999.
34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
35. Loader C. Local regression and likelihood (statistics and computing). New York: Springer; 1999.
36. US Department of Health and Human Services, National Center for Health Statistics. The National Health and Nutrition Examination Survey (NHANES): analytic and reporting guidelines. Hyattsville, Maryland: US Department of Health and Human Services, National Center for Health Statistics; 2006.
37. Turnbull B. The empirical distribution with arbitrarily grouped, censored and truncated data. J Royal Stat Soc Ser B 1976; 38:290-295.
38. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, et al. CDC growth charts: United States. Adv Data 2000:1-27.
39. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89:495-501.
40. Botton J, Heude B, Kettaneh A, Borys JM, Lommez A, Bresson JL, et al. Cardiovascular risk factor levels and their relationships with overweight and fat distribution in children: the Fleurbaix Laventie Ville Sante II study. Metabolism 2007; 56:614-622.
41. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care 2000; 23:381-389.
42. Carter RJ, Wiener J, Abrams EJ, Farley J, Nesheim S, Palumbo P, Bulterys M. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1994-2004: a longitudinal analysis. J Acquir Immune Defic Syndr 2006; 41:453-460.
43. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007; 115: 1948-1967.
44. Webber LS, Harsha DW, Phillips GT, Srinivasan SR, Simpson JW, Berenson GS. Cardiovascular risk factors in Hispanic, white, and black children: the Brooks County and Bogalusa Heart studies. Am J Epidemiol 1991; 133:704-714.
45. Webber LS, Osganian V, Luepker RV, Feldman HA, Stone EJ, Elder JP, et al. Cardiovascular risk factors among third grade children in four regions of the United States. The CATCH Study. Child and Adolescent Trial for Cardiovascular Health. Am J Epidemiol 1995; 141:428-439.
46. Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122:198-208.
47. CDC. Trends in HIV- and STD-related risk behaviors among high school students: United States, 1991-2007. MMWR Morb Mortal Wkly Rep 2008; 57:817-822.
48. Laurson KR, Eisenmann JC, Welk GJ, Wickel EE, Gentile DA, Walsh DA. Combined influence of physical activity and screen time recommendations on childhood overweight. J Pediatr 2008; 153:209-214.
49. Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31:257-275.
50. Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002; 346:802-810.
51. UwaifoGI, ElbergJ, Yanovski JA. Impaired glucose tolerance in obese children and adolescents. N Engl J Med 2002; 347:290- 292; author reply 290-292.
52. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350:2362- 2374.
53. Rosso R, Parodi A, d'Annunzio G, Ginocchio F, Nicolini L, Torrisi C, et al. Evaluation of insulin resistance in a cohort of HIV-infected youth. Eur J Endocrinol 2007; 157:655-659.
54. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100:700-705.
55. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, et al. Effect of ritonavir on lipids and postheparin lipase activities in normal subjects. AIDS 2000; 14:51-57.
56. Lee GA, Lo JC, Aweeka F, SchwarzJM, Mulligan K, Schambelan M, Grunfeld C. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis 2006; 43:658-660.
57. Lee GA, Rao M, Mulligan K, Lo JC, Aweeka F, Schwarz JM, et al. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS 2007; 21:2183-2190.
58. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV- infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Diabetes Care 2008; 31:1224- 1229.
59. Brambilla P, Bricalli D, Sala N, Renzetti F, Manzoni P, Vanzulli A, et al. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 2001; 15:2415-2422.
60. Vigano A, Brambilla P, Cafarelli L, Giacomet V, Borgonovo S, Zamproni I, et al. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz. Antivir Ther 2007; 12:297-302.
61. Mulligan K, Anastos K, Justman J, Freeman R, Wichienkuer P, Robison E, Hessol NA. Fat distribution in HIV-infected women in the United States: DEXA substudy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2005; 38:18-22.
62. Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121 -131.
63. Vigano A, Mora S, Brambilla P, Schneider L, Merlo M, Monti LD, Manzoni P. Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents. AIDS 2003; 17:1435-1441.
64. Arpadi SM, Horlick MN, Wang J, Cuff P, Bamji M, Kotler DP. Body composition in prepubertal children with human immunodeficiency virus type 1 infection. Arch Pediatr Adolesc Med 1998; 152:688-693.
65. Stewart KJ, Goldberg AP. Exercise, lipids, and obesity in adolescents with parental history of coronary disease. Am J Health Promot 1992; 6:430-436.
66. Stewart KJ. Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. JA MA 2002; 288:1622-1631.
67. Sung RY, Yu CW, Chang SK, Mo SW, Woo KS, Lam CW. Effects of dietary intervention and strength training on blood lipid level in obese children. Arch Dis Child 2002; 86:407-410.
68. Kelly AS, Wetzsteon RJ, Kaiser DR, Steinberger J, Bank AJ, Dengel DR. Inflammation, insulin, and endothelial function in overweight children and adolescents: the role of exercise. J Pediatr 2004; 145:731-736.
69. Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C, White RD. Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 2006; 29:1433-1438.
70. Roberts CK, Chen AK, Barnard RJ. Effect of a short-term diet and exercise intervention in youth on atherosclerotic risk factors. Atherosclerosis 2007; 191:98-106.